The reiteration of an Outperform rating and maintenance of an $18 price target by a reputable analyst like Etzer Darout from BMO Capital is likely to instill confidence among investors and could positively influence Acrivon Therapeutics' stock price in the short term. Analyst ratings, especially those that are positive and come with a significant price target, often lead to increased investor interest and can drive up the stock price.